The Tumor Stroma

Biology and Therapeutics
1. Auflage 2022
ISBN: 978-981-4968-06-5
Verlag: Jenny Stanford Publishing

Buch, Englisch, 446 Seiten, Format (B × H): 157 mm x 235 mm, Gewicht: 792 g

The identification of the role of tumor stroma—the tissue in the surroundings of cancer cells—in cancer development, progression, and metastasis has revolutionized the fields of cancer biology as well as cancer therapeutics. This book provides a comprehensive overview of this rapidly-evolving field including tumor stroma biology, therapeutic targets, molecular imaging, and advanced tumor stroma in vitro models. The book will serve as a handbook for graduate students, postgraduate researchers, pharmaceutical scientists, and biomedical engineers.

Zielgruppe

Academic and Postgraduate

Autoren/Hrsg.

Prakash, Jai

Fachgebiete

• Naturwissenschaften Biowissenschaften Zellbiologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin
• Naturwissenschaften Biowissenschaften Biowissenschaften

Inhaltsverzeichnis

1. The Tumor Stroma: Key Component of Solid Tumors 2. Cancer-Associated Fibroblasts: Building Blocks of the Tumor Stroma 3. Tumor-Associated Macrophages: Biological Understanding and Therapeutic Opportunities 4. Biomarkers in the Tumor Stroma and Their Clinical Relevance 5. Physical Properties of the Tumor Stroma and Therapeutic Strategies 6. TGF-ß Signalling in Cancer: Role and Therapeutic Targeting of the Tumour Stroma 7. Role of Integrins in the Tumor Stroma 8. MicroRNA in the Tumor Stroma: Diagnostic and Therapeutic Implications 9. Molecular Imaging of the Tumor Stroma and Beyond 10. 3D in vitro Models to Mimic the Tumor Microenvironment

Über Autor(innen)

Jai Prakash, Professor at the University of Twente in the Netherlands, is a pharmaceutical and bioentrepreneurial scientist working in the field of engineered therapeutics against cancer and fibrosis. He is educated as a pharmacologist and obtained his PhD (with honors) from the University of Groningen, the Netherlands. Earlier, he worked as vice president at BiOrion Technologies and Assistant Professor at Karolinska Institutet, Sweden, and then joined as a tenure track professor at the University of Twente. He is also a founder and CSO of ScarTec Therapeutics and the president of BeNeLux and France local chapter for the Controlled Release Society (CRS). His research interests are in designing therapeutic technologies to disrupt the crosstalk between tumor cells and stromal cells and in developing advanced 3D in vitro models to mimic the tumor microenvironment.